Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Capital Expenditures (2022 - 2025)

TriSalus Life Sciences' Capital Expenditures history spans 4 years, with the latest figure at $5000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 98.55% year-over-year to $5000.0; the TTM value through Dec 2025 reached $68000.0, down 80.29%, while the annual FY2025 figure was $68000.0, 80.29% down from the prior year.
  • Capital Expenditures reached $5000.0 in Q4 2025 per TLSIW's latest filing, up from -$598000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $754000.0 in Q1 2025 to a low of -$598000.0 in Q3 2025.
  • Average Capital Expenditures over 4 years is $43230.8, with a median of $31000.0 recorded in 2023.
  • The largest YoY upside for Capital Expenditures was 1042.42% in 2025 against a maximum downside of 374.6% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at -$439000.0 in 2022, then soared by 184.74% to $372000.0 in 2023, then fell by 7.26% to $345000.0 in 2024, then plummeted by 98.55% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Capital Expenditures are $5000.0 (Q4 2025), -$598000.0 (Q3 2025), and -$93000.0 (Q2 2025).